3 Stocks That Could Turn $1,000 Into $5,000 by 2030
Key Points
The leisure cruise industry is faring far better than it seems like it should be, and an unlikely Carnival is leading the way.
Although Iovance Biotherapeutics shares have never been lower, the company's never been more promising than it is right now.
Shopify is capitalizing on a shift in the e-commerce business with all the right technological tools.
Experienced investors understand that being in the stock market requires a long-term, multiyear mindset. For truly patient people though, the reward is well worth the wait; you'd be hard-pressed to find better returns on your money than the market's average annual gain of about 10%.
Still, sometimes you get the itch for a bit more gain reaped in a little less time. And every now and then the market obliges with the right prospects.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
If you can stomach their above-average risk, there are stocks that have the potential to quintuple your money within the next five years. Even half of that, of course, would still be worth your while.
Carnival Corp.
Anyone who knows anything about Carnival Corp. (NYSE: CCL) knows the leisure cruise company took on a ton of debt during and because of the COVID-19 pandemic. It needed the cash just to survive. As of May the $40 billion company was sitting on nearly $26 billion worth of long-term obligations costing it roughly $1.4 billion worth of interest payments per year. That's a pretty big bite out of its annualized top line of almost $16 billion, paring its yearly net income back to something in the ballpark of $3 billion. That's why shares are still down on the order of 30% from their price right before the pandemic took hold, and less than half of their 2018 peak price -- investors are simply worried its balance sheet is untenable.
The thing is, this profitable company is managing to continue paying down its debt while also still growing its business. At its early 2023 peak, for perspective, Carnival's long-term debt stood at nearly $33 billion.
While there's obviously plenty of more work to be done before the company is back to its pre-pandemic condition, the demand it requires to do so is most definitely in place. Last quarter's record-breaking revenue of $6.3 billion was turned into record-breaking operating income of over $900 million, extending an ongoing streak of growth for both measures. Look for more of the same, too. See, also as of the end of last quarter the company's total customer deposits toward future trips reached a record-breaking $8.5 billion.
What gives? As it turns out, consumers are still seeking out affordable luxury experiences even if money is tight. The Cruise Lines International Association believes the industry will serve 37.7 million passengers this year, breaking last year's record of 34.6 million en route to 41.9 million in 2028. Carnival is well positioned to capture at least its fair share of this growth.
Just don't tarry if you're interested. More and more investors are seeing this dynamic, given how shares are well up from their 2022 low and still climbing.
Iovance Biotherapeutics
There's a good chance you've never heard of Iovance Biotherapeutics (NASDAQ: IOVA). Its billion-dollar market cap just doesn't turn many heads, and for those who do find it, the unprofitable biopharma outfit with only one expensive therapy in its portfolio seems like anything but a sure thing.
If there was ever a one-trick pony to take a shot on though, this one may be it.
It's called Amtagvi. Only approved early last year, this drug is the first Food and Drug Administration (FDA)-approved cellular therapy (tumor-infiltrating lymphocytes, specifically) to treat certain kinds of melanoma. The underlying science, however, is promising on far more fronts. Amtagvi -- generically called lifileucel -- is also being tested in a dozen other clinical trials, while similarly made treatments are in the midst of eight more testing regimens. And some of these trials are in their latter stages, like the use of lifileucel as a treatment for certain sorts of non-responsive lung cancer.

Image source: Getty Images.
There is a challenge. That is, Amtagvi is complicated to administer, and expensive. Each patient's one-time treatment is custom-made in a lab for their particular tumor at a cost of around $500,000 apiece. Some insurers are balking, particularly given that it's still a relatively new medicine, and not a more proven "front line" therapy that's also often much cheaper. Anyone who's been watching this company for a while also knows this stock's performed poorly since its 2010 initial public offering (IPO), and even since its 2020 rally when Amtagvi's approval first became imminent.
The fact is, however, Iovance Biotherapeutics' future has never been brighter than it is right now, yet the stock's never been cheaper. The company's also never been closer to profitability than it is at this time. Analysts are expecting bottom-line progress that puts it on a trajectory for a swing to profitability sometime around or even before 2030, when research from Global Data suggests sales of Amtagvi could exceed $1 billion en route to as much as $2 billion per year. This prospect alone is enough to turn up the heat on Iovance stock in the meantime.
Shopify
Finally, add Shopify (NASDAQ: SHOP) to your list of stocks that could turn $1,000 into $5,000 by 2030. The analyst community expects its top line to grow to the tune of 20% per year for the next several years, pumping up its profits at an even faster rate.
It's possible you've used the company's technology without even realizing it. In contrast with Amazon's business model, Shopify helps brands and merchants build their own online stores. This allows for far more customization of the e-commerce experience, ultimately building a stronger -- and more direct -- relationship with consumers as they become customers. Although the company no longer discloses the figure, estimates of the number of online stores put the figure somewhere around 5 million.
The company does, however, still disclose how much business its platform is facilitating. Last year, Shopify's e-commerce technology handled $292.3 billion worth of business on behalf of its customers, generating $8.9 billion worth of revenue for itself. Those numbers were up 24% and 26% (respectively) year over year, extending growth trends that are expected to persist for a long while more.
The key to this growth is the way e-commerce is evolving in the wake of Amazon's heavy-handed dominance of the business.
In its early days Amazon.com was the premier platform for connecting with consumers. As time has marched on, however, Amazon is decreasingly a partner with its sellers, and increasingly a competitor to them. Not only does the e-commerce giant now sell its own merchandise, but it offers third-party sellers the option of paying the company to more prominently feature their goods at the site. Smaller sellers without much of a marketing budget often just can't compete. The issue of fake product reviews also remains a nuisance. All of this dynamic ultimately helps Shopify, of course, by prompting sellers to look for sales platforms where they have more cost-effective control.
Then there's the more philosophical aspect of e-commerce's ongoing evolution. As the industry changes it's increasingly moving toward greater authenticity and more personal connections with consumers. This of course favors Shopify's customizable offerings, and is one of the reasons IMARC Group believes the world's direct-to-consumer market that Shopify serves will grow at an average annualized pace of more than 17% through 2033. Shopify is well positioned to win more than its fair share of this growth.
Should you invest $1,000 in Carnival Corp. right now?
Before you buy stock in Carnival Corp., consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Carnival Corp. wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,108,033!*
Now, it’s worth noting Stock Advisor’s total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of August 4, 2025
James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Iovance Biotherapeutics, and Shopify. The Motley Fool recommends Carnival Corp. The Motley Fool has a disclosure policy.